Severity but not comorbidities predicts response to methylphenidate in adults with attention-deficit/hyperactivity disorder: Results from a naturalistic study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 212-217

  Victor, Marcelo M ^a   Rovaris, Diego L ^b   Salgado, Carlos A I ^a   Silva, Katiane L ^a   Karam, Rafael G ^a   Vitola, Eduardo S ^a   Picon, Felipe A ^a   Contini, Verônica ^c   Guimarães Da Silva, Paula O ^a   Blaya Rocha, Paula ^a   Belmonte De Abreu, Paulo S ^b   Rohde, Luis A ^b,d   Grevet, Eugenio H ^a,b   Bau, Claiton H D ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c CENTRO UNIVERSITÁRIO UNIVATES   (Brazil)

^d National Institute of Developmental Psychiatry for Children and Adolescents (INPD/Brazil)   (Brazil)

Author keywords

ADHD; Adult; Comorbidities; Methylphenidate; Treatment

Indexed keywords

METHYLPHENIDATE;

ADULT; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SMOKING; STRUCTURED INTERVIEW; SWANSON NOLAN AND PELHAM RATING SCALE; TREATMENT RESPONSE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; FEMALE; HUMANS; MALE; MENTAL DISORDERS; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896375545     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000091     Document Type: Article

References (47)

1. Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3): 204-211.
2. Almeida Montes LG, Hernández García AO, Ricardo-Garcell J. ADHD prevalence in adult outpatients with nonpsychotic psychiatric illnesses. J Atten Disord. 2007;11(2): 150-156.
3. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011;25(2): 157-169.
4. NICE. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. 2008 Available at: http://www.nice.org.uk/nicemedia/live/12061/42060/42060.pdf. Accessed December 2012.
5. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21(1): 10-41.
6. Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, et al. Predictors of treatment outcome in adults with ADHD treated with OROS\ methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2): 554-560.
7. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10(3): 286-294.
8. Carpentier PJ, de Jong CA, Dijkstra BA, et al. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction. 2005;100(12): 1868-1874.
9. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006;81(2): 137-148.
10. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007;87(1): 20-29.
11. Biederman J, Mick E, Spencer T, et al. Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD. CNS Neurosci Ther. 2012;18(2): 126-132.
12. Marchant BK, Reimherr FW, Halls C, et al. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann Clin Psychiatry. 2010;22(3): 196-204.
13. Robison RJ, Reimherr FW, Gale PD, et al. Personality disorders in ADHD Part 2: the effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD. Ann Clin Psychiatry. 2010;22(2): 94-102.
14. Marchant BK, Reimherr FW, Robison RJ, et al. Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord. 2011;15(4): 295-304.
15. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68(1): 93-101.
16. Victor MM, Grevet EH, Salgado CA, et al. Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/ hyperactivity disorder: the role of comorbidities. J Clin Psychopharmacol. 2009;29(6): 614-616.
17. Mercadante MT, Asbarh F, Rosário MC, et al. K-SADS, Entrevista Semi-Estruturada para Diagnó stico em Psiquiatria da Infância, versão Epidemiológica. São Paulo, Brazil: PROTOCYHospital das Clínicas da FMUSP; 1995.
18. Grevet EH, Bau CH, Salgado CA, et al. Lack of gender effects on subtype outcomes in adults with attention-deficit/hyperactivity disorder: support for the validity of subtypes. Eur Arch Psychiatry Clin Neurosci. 2006;256(5): 311-319.
19. Grevet EH, Bau CH, Salgado CA, et al. Interrater reliability for diagnosis in adults of attention deficit hyperactivity disorder and oppositional defiant disorder using K-SADS-E. Arq Neuropsiquiatr. 2005;63(2A): 307-310.
20. Kieling C, Kieling RR, Rohde LA, et al. The age at onset of attention deficit hyperactivity disorder. Am J Psychiatry. 2010;167(1): 14-16.
21. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161(11): 1948-1956.
22. Karam RG, Bau CH, Salgado CA, et al. Late-onset ADHD in adults: milder, but still dysfunctional. J Psychiatr Res. 2009;43(7): 697-701.
23. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P, Version 2.0, 8/98 revision). New York, NY: Biometric Research Department, New York State Psychiatric Institute; 1998.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IVand ICD-10. J Clin Psychiatry. 1998;59(suppl 20): 22-33.
25. Wechsler D. WAIS-R: Manual for the Wechsler Adult Intelligence Scale, Revised. San Antonio, TX: The Psychological Corporation; 1981.
26. Mattos P, Palmini A, Salgado CA, et al. Brazilian consensus of specialists on the diagnosis of attention-deficit/hyperactivity disorder in adults. Rev Psiquiatr Rio Gd Sul [online]. 2006;28(1): 50-60. Available at: http://www.scielo.br/pdf/rprs/v28n1/en-v28n1a07.pdf. Accessed December 2012.
27. Polanczyk G, Zeni C, Genro JP, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64: 218-224.
28. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40: 168-179.
29. Gibbins C, Weiss M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep. 2007;9(5): 420-426.
30. Newcorn JH. Managing ADHD and comorbidities in adults. J Clin Psychiatry. 2009;70(2): e40.
31. Nielsen T, Karpatschof B, Kreiner S. Regression to the mean effect: when to be concerned and how to correct for it. Nordic Psychology. 2007;59(3): 231-250.
32. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34: 215-220.
33. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999;37(6): 457-470.
34. Townsend JD, Sugar CA, Walshaw PD, et al. Frontostriatal neuroimaging findings differ in patients with bipolar disorder who have or do not have ADHD comorbidity. J Affect Disord. 2013;147(1-3): 389-396.
35. Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naBve boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology. 2011;36(8): 1575-1586.
36. Looby A, Earleywine M. Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance. Exp Clin Psychopharmacol. 2011;19(6): 433-444.
37. Volkow ND, Wang GJ, Ma Y, et al. Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage. 2006;32(4): 1782-1792.
38. Buitelaar JK, Sobanski E, Stieglitz RD, et al. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. J Clin Psychiatry. 2012;73(8): 1097-1102.
39. Steinman SA, Smyth FL, Bucks RS, et al. Anxiety-linked expectancy bias across the adult lifespan. Cogn Emot. 2013;27(2): 345-355.
40. Carter GC, Cantrell RA, Zarotsky V, et al. Comprehensive review of factors implicated in the heterogeneity of response in depression. Depress Anxiety. 2012;29(4): 340-354.
41. Taylor S, Abramowitz JS, McKay D. Non-adherence and non-response in the treatment of anxiety disorders. J Anxiety Disord. 2012;26(5): 583-589.
42. Patrick KS, González MA, Straughn AB, et al. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv. 2005;2(1): 121-143.
43. Kemner JE, Lage MJ. Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann Gen Psychiatry. 2006;5: 5.
44. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5): 456-463.
45. Fukui S, Shimizu Y, Rapp CA. A cross-cultural study of recovery for people with psychiatric disabilities between U.S. and Japan. Community Ment Health J. 2012;48(6): 804-812.
46. Drago A, Serretti A. Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial. J Clin Psychopharmacol. 2011;31(3): 345-348.
47. Wade AG, Johnson PC, McConnachie A. Antidepressant treatment and cultural differencesVa survey of the attitudes of physicians and patients in Sweden and Turkey. BMC Fam Pract. 2010;11: 93.